Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Heplisav-B Review Still On Track Even After Cancelled Advisory Cmte., Dynavax Says

Executive Summary

FDA calls off November meeting to give 'more time to review and resolve several outstanding issues' with adjuvanted hepatitis B vaccine; Dynavax says agency determined meeting was not necessary to ensure regulatory decision by Dec. 15 goal date.


Related Content

Heplisav Vaccine Postmarketing Study Might Overcome FDA Safety Worries At Panel
Valbenazine FDA Panel Cancellation Is A Good Sign, Neurocrine Says
US FDA Review Management Challenged After Spate Of Complete Response Letters
Keeping Track: FDA Approves First Rx DHEA, Receives Applications For Midostaurin, Gesulkumab, Biosimilar Avastin
From Solanezumab To Solithromycin: What To Watch For In Q4
Stockwatch: Dynavax, CoLucid Investors Should Beware The Standard Of Care
Dynavax Hep B Vaccine Gets Second Panel Review; Scrutiny On Safety, Superiority
Will Dynavax’ HBV Vaccine Resubmission Make The Safety Grade?
FDA Panel Considers Dynavax’s Heplisav Safety Database Insufficient
Merck Returns Heplisav To Dynavax After FDA Rules Vaccine Too Risky For Healthy Adults


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts